The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...

FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.

Failure to recognize and resolve problems in an honest and evidence-based manner is the root cause of increasing vaccine ...

Kennedy selected a new team of medical professionals and scientists who are looking at vaccines are highly qualified.

The update covers the safety and appropriate timing of vaccinations, screening for osteoporosis, cervical cancer, skin cancer ...

Vaccines do much more than prevent specific diseases — their side benefits save children's lives around the world ...

RSV is causing thousands of infant deaths in India yearly, yet remains underdiagnosed. Experts stress the urgent need for ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50, down from 60, following ...

Traditionally, individuals asked health questions of their primary health care provider. Confidence in that provider as a source of trustworthy health ...

If I have sounded like a broken record these past months, it is because these developments in American public health are as ...

The CDC already recommends the RSV shot for all adults 75 and older and for people 60 and older who have health conditions that increase their risk of severe RSV. It also recommends the shot during ...